

Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Tokyo, April 28, 2023
Alfresa Holdings Corporation

Notice regarding Revisions to the Consolidated Performance Forecast (Prepared Based on Japan's Generally Accepted Accounting Principles (GAAP))

Due to the current business environment, the Company revised its consolidated performance forecast for the full year ended March 31, 2023 (April 1, 2022–March 31, 2023), which was announced on May 16, 2022. Please note that although the fiscal year ended March 31, 2023, has concluded, final financial results are yet to be published.

1. Revisions of the Consolidated Performance Forecast for the Full Year Ended March 31, 2023

	Net sales	Operating income	Ordinary profit	Profit attributable to owners of the parent	Basic earnings per share
	¥ Million	¥ Million	¥ Million	¥ Million	Yen
Previous projection (A)	2,618,000	29,500	32,800	21,200	104.76
Revised projection (B)	2,698,000	30,100	32,800	25,700	127.00
Change (B-A)	80,000	600	0	4,500	—
Percentage change (%)	3.1	2.0	0	21.2	—
(Ref.) Results for the full year ended March 31, 2022	2,585,643	29,091	32,576	32,182	153.57

2. Reason for Revisions of the Consolidated Performance Forecast

Regarding the consolidated financial results for the fiscal year ended March 31, 2023, net sales and operating income are expected to exceed the previous forecast. This is attributed to greater-than-expected growth in the market for ethical pharmaceuticals, the Company's recovery from the bidding nomination suspension from medical institutions stemming from a violation of the Antimonopoly Act, and growth in the medical goods field. Profit attributable to owners of the parent is also expected to exceed the previous forecast by a significant amount due to the reasons above, as well as a considerable increase in extraordinary income from the sale of investment securities conducted as part of the Company's ongoing effort to reduce cross-shareholdings.

Note: Disclaimer regarding the Appropriate Use of Performance Forecasts and Other Notes

The forward-looking statements, such as performance forecasts contained herein, are forecasts based on information currently possessed by the Company and are based on certain assumptions deemed to be reasonable. Actual performance may differ substantially from these forecasts due to various factors.

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported its consolidated revenue of ¥2.5 trillion (US\$21 billion) for the fiscal year ended March 31, 2022. For more information, please see: <https://www.alfresa.com/eng/>